Insider Transactions in Q1 2026 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
Fred E Cohen |
BUY
Open market or private purchase
|
Direct |
150,000
+41.96%
|
$1,350,000
$9.35 P/Share
|
|
Jan 05
2026
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,397
-9.29%
|
$93,573
$9.21 P/Share
|
|
Jan 05
2026
|
Birgit C Schultes EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,508
-7.95%
|
$76,572
$9.21 P/Share
|
|
Jan 05
2026
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
34,146
-3.26%
|
$307,314
$9.21 P/Share
|
|
Jan 05
2026
|
Michael P Dube VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,989
-5.41%
|
$26,901
$9.21 P/Share
|
|
Jan 05
2026
|
Edward J Dulac Iii EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,379
-6.01%
|
$57,411
$9.21 P/Share
|
|
Jan 05
2026
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
9,515
-9.85%
|
$85,635
$9.21 P/Share
|
|
Jan 05
2026
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,903
-8.94%
|
$107,127
$9.21 P/Share
|